222
Participants
Start Date
September 2, 2022
Primary Completion Date
June 29, 2024
Study Completion Date
June 29, 2024
Beovu
Prospective observational study. There was no treatment allocation. Patients prescribed with Beovu for the first time for diabetic macular edema were eligible to enroll into this study.
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Nagakute
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Kashiwa
Novartis Investigative Site, Kisarazu
Novartis Investigative Site, Urayasu
Novartis Investigative Site, Urayasu
Novartis Investigative Site, Yoshida-gun
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Kurume
Novartis Investigative Site, Fukushima
Novartis Investigative Site, Mizunami
Novartis Investigative Site, Maebashi
Novartis Investigative Site, Asahikawa
Novartis Investigative Site, Hakodate
Novartis Investigative Site, Hakodat
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Kobe
Novartis Investigative Site, Kobe
Novartis Investigative Site, Nishinomiya
Novartis Investigative Site, Sumoto
Novartis Investigative Site, Takarazuka
Novartis Investigative Site, Inashiki
Novartis Investigative Site, Ishioka
Novartis Investigative Site, Mito
Novartis Investigative Site, Kita-gun
Novartis Investigative Site, Kagoshima
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Nankoku
Novartis Investigative Site, Arao
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Yokkaichi
Novartis Investigative Site, Miyakonojō
Novartis Investigative Site, Matsumoto
Novartis Investigative Site, Ueda
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Nagasaki
Novartis Investigative Site, Kashihara
Novartis Investigative Site, Jōetsu
Novartis Investigative Site, Sanjō
Novartis Investigative Site, Ōita
Novartis Investigative Site, Yufu
Novartis Investigative Site, Kurashiki
Novartis Investigative Site, Okayama
Novartis Investigative Site, Hirakata
Novartis Investigative Site, Moriguchi
Novartis Investigative Site, Osaka
Novartis Investigative Site, Ōsaka-sayama
Novartis Investigative Site, Sakai
Novartis Investigative Site, Suita
Novartis Investigative Site, Iruma-gun
Novartis Investigative Site, Ohtsu
Novartis Investigative Site, Oda
Novartis Investigative Site, Shimotsuke
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Chiyoda-ku
Novartis Investigative Site, Edogawa City
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Itabashi-ku
Novartis Investigative Site, Katsushika-ku
Novartis Investigative Site, Musashino
Novartis Investigative Site, Taito-ku
Novartis Investigative Site, Toyama
Novartis Investigative Site, Akita
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Okayama
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY